{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:15:26Z","timestamp":1790342126452,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bcp.2019.03.027","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T12:41:54Z","timestamp":1553085714000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Treatment of polymyalgia rheumatica"],"prefix":"10.1016","volume":"165","author":[{"given":"Santos","family":"Casta\u00f1eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Garc\u00eda-Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Prieto-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Mart\u00ednez-Quintanilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther F.","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.03.027_b0005","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Gonz\u00e1lez-Gay","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.03.027_b0010","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0020","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of polymyalgia rheumatica 2000\u20132014 and examination of incidence and survival trends over 45 years: a population based study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res. (Hoboken)."},{"key":"10.1016\/j.bcp.2019.03.027_b0025","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/art.1780300308","article-title":"Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county: a prospective investigation, 1982\u20131985","volume":"30","author":"Boesen","year":"1987","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0030","first-page":"112","article-title":"Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection","volume":"23","author":"Elling","year":"1996","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/rheumatology\/34.3.261","article-title":"Epidemiology and mortality in 220 patients with polymyalgia rheumatica","volume":"34","author":"Schaufelberger","year":"1995","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.1780340313","article-title":"Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy","volume":"34","author":"Salvarani","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0045","first-page":"1326","article-title":"The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study","volume":"26","author":"Gonzalez-Gay","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","article-title":"Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015","volume":"47","author":"Crowson","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12891-016-1127-3","article-title":"The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population","volume":"17","author":"Yates","year":"2016","journal-title":"BMC Musculoskelet Disord."},{"key":"10.1016\/j.bcp.2019.03.027_b0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/sarh.2002.50025","article-title":"Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica","volume":"33","author":"Gonz\u00e1lez-Gay","year":"2003","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0065","first-page":"580","article-title":"Polymyalgia rheumatica\u2013a clinical study with particular reference to arterial disease","volume":"11","author":"Mowat","year":"1984","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/ard.49.7.521","article-title":"A seasonal pattern in the onset of polymyalgia rheumatica","volume":"49","author":"Cimmino","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semarthrit.2003.09.007","article-title":"Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions","volume":"33","author":"Gonzalez-Gay","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W","article-title":"Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study","volume":"41","author":"Salvarani","year":"1998","journal-title":"Arthritis Rheum."},{"issue":"9634","key":"10.1016\/j.bcp.2019.03.027_b0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.03.027_b0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4081\/reumatismo.2018.1040","article-title":"Imaging in polymyalgia rheumatica","volume":"70","author":"Possemato","year":"2018","journal-title":"Reumatismo"},{"key":"10.1016\/j.bcp.2019.03.027_b0095","first-page":"517","article-title":"Polymyalgia rheumatica: a disorder of extraarticular synovial structures?","volume":"26","author":"Salvarani","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0100","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/art.1780390719","article-title":"Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment","volume":"39","author":"Meliconi","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","article-title":"Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis","volume":"121","author":"Weyand","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0110","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1002\/art.27728","article-title":"Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica","volume":"62","author":"Kreiner","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0115","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0120","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/art.38625","article-title":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica","volume":"66","author":"Van der Geest","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.bcp.2019.03.027_b0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11926-014-0480-1","article-title":"Giant cell arteritis and polymyalgia rheumatica: an update","volume":"17","author":"Gonz\u00e1lez-Gay","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"issue":"9860","key":"10.1016\/j.bcp.2019.03.027_b0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(12)60680-1","article-title":"Polymyalgia rheumatica","volume":"381","author":"Kermani","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.03.027_b0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.1780390110","article-title":"Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report of nineteen cases","volume":"39","author":"Salvarani","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bcp.2019.03.027_b0140","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1001\/jama.1985.03360190069027","article-title":"Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome","volume":"254","author":"McCarty","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2019.03.027_b0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archinte.1997.00440240081012","article-title":"Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome","volume":"157","author":"Gonz\u00e1lez-Gay","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0150","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","article-title":"Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica","volume":"54","author":"Van der Geest","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2019.03.027_b0155","first-page":"276","article-title":"Diagnostic approach in a patient presenting with polymyalgia","volume":"17","author":"Gonzalez-Gay","year":"1999","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0160","first-page":"755","article-title":"Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatica","volume":"18","author":"Gonz\u00e1lez-Gay","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0165","first-page":"2179","article-title":"The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain","volume":"27","author":"Gonzalez-Gay","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0170","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0002-9343(99)00424-6","article-title":"Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch","volume":"108","author":"Blockmans","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0175","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3109\/03009742.2013.850737","article-title":"Large vessel vasculitis and spondyloarthritis: coincidence or associated diseases?","volume":"43","author":"Ernst","year":"2014","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0180","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","article-title":"Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2019.03.027_b0185","first-page":"1750","article-title":"Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica","volume":"25","author":"Gonz\u00e1lez-Gay","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0190","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","article-title":"2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"64","author":"Dasgupta","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f6937","article-title":"Polymyalgia rheumatica","volume":"347","author":"Mackie","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2019.03.027_b0200","first-page":"1049","article-title":"Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study","volume":"28","author":"Cantini","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0205","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kep286","article-title":"Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica","volume":"48","author":"Macchioni","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2019.03.027_b0210","first-page":"120","article-title":"Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica","volume":"31","author":"Cantini","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0215","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","article-title":"Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients","volume":"46","author":"Blockmans","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2019.03.027_b0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","article-title":"Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients","volume":"55","author":"Blockmans","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rdc.2015.08.009","article-title":"Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis","volume":"42","author":"Matteson","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.bcp.2019.03.027_b0230","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14656561003724739","article-title":"Medical management of polymyalgia rheumatica","volume":"11","author":"Gonzalez-Gay","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2019.03.027_b0235","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.39333","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"67","author":"Dejaco","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0240","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/21678707.2016.1244480","article-title":"Managing of giant cell arteritis and polymyalgia rheumatica","volume":"4","author":"Gonz\u00e1lez-Gay","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.bcp.2019.03.027_b0245","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0250","first-page":"1","article-title":"Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice","volume":"35","author":"Yates","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0255","first-page":"1492","article-title":"Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens","volume":"22","author":"Di Munno","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0260","first-page":"1660","article-title":"A long-term prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica","volume":"22","author":"Krogsgaard","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0265","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000426","article-title":"Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study","volume":"3","author":"Cutolo","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.bcp.2019.03.027_b0270","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/37.2.189","article-title":"An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica","volume":"37","author":"Dasgupta","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0275","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0280","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"Van der Veen","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0285","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0290","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0295","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0300","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","article-title":"Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR)","volume":"33","author":"Lee","year":"2013","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bcp.2019.03.027_b0305","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/120638","article-title":"Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series","volume":"2013","author":"Diamantopoulos","year":"2013","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bcp.2019.03.027_b0310","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study","volume":"30","author":"Salvarani","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0315","first-page":"373","article-title":"TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and\/or osteoporosis: a seven cases report","volume":"9","author":"Migliore","year":"2005","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2019.03.027_b0320","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0325","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0330","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0335","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0340","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bcp.2019.03.027_b0345","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0350","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0355","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/BOR.0b013e32835b133a","article-title":"New treatment strategies in large-vessel vasculitis","volume":"25","author":"Unizony","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0360","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: the first interleukin-6-receptor inhibitor","volume":"65","author":"Sebba","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.bcp.2019.03.027_b0365","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","article-title":"Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients","volume":"44","author":"Loricera","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0370","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3899\/jrheum.151252","article-title":"Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients","volume":"43","author":"R\u00e9gent","year":"2016","journal-title":"J. Rheumatol."},{"issue":"10031","key":"10.1016\/j.bcp.2019.03.027_b0375","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.03.027_b0380","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semarthrit.2013.01.003","article-title":"Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature","volume":"43","author":"Macchioni","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0390","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s10067-014-2650-y","article-title":"Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy","volume":"35","author":"Mori","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0395","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0400","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"3 Suppl. 82","key":"10.1016\/j.bcp.2019.03.027_b0405","first-page":"S79","article-title":"Tocilizumab in refractory aortitis: study on 16 patients and literature review","volume":"32","author":"Loricera","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0410","first-page":"S391","article-title":"A two-week single-blind, randomized 3-arm proof of concept study of the effects of secukinumab (anti-IL17 mAb), canakinumab (anti-IL-1 b mAb), or corticosteroids on initial disease activity scores in patients with PMR, followed by an open-label extension","volume":"66","author":"Matteson","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0415","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0420","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2019.03.027_b0425","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0430","unstructured":"B. Hartmann, J. Liao, M.H. Weisman,K.J. Warrington, J.J. Goronzy, C.M. Weyand. The STAT1 Signaling Pathway In Giant Cell Arteritis. Meeting: 2013 ACR\/ARHP Annual Meeting; Abstract Number#1691."},{"key":"10.1016\/j.bcp.2019.03.027_b0435","doi-asserted-by":"crossref","DOI":"10.7326\/AITC201705020","article-title":"Polymyalgia rheumatica","volume":"166","author":"Matteson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.03.027_b0440","first-page":"S29","article-title":"Novel glucocorticoids: where are we now and where do we want to go?","volume":"33","author":"Buttgereit","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bcp.2019.03.027_b0445","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pharmthera.2015.05.001","article-title":"Selective glucocorticoid receptor modulation: new directions with non-steroidal scaffolds","volume":"152","author":"Sundahl","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2019.03.027_b0450","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1021\/mp2000742","article-title":"Liposomal drug formulations in the treatment of rheumatoid arthritis","volume":"8","author":"Van den Hoven","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2019.03.027_b0455","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1756-185X.13149","article-title":"A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis","volume":"21","author":"Raine","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0460","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1742-1241.2012.02981.x","article-title":"Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series","volume":"66","author":"Adizie","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.bcp.2019.03.027_b0465","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","article-title":"Rheumatologic symptoms in oncologic patients on PD-1 inhibitors","volume":"47","author":"Kuswanto","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.03.027_b0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2019.03.027_b0475","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0480","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2019.03.027_b0485","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"FHU ACRONIM. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2019.03.027_b0490","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:09:55Z","timestamp":1757768995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219301133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":98,"alternative-id":["S0006295219301133"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.03.027","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of polymyalgia rheumatica","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}